Mycapssa
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.mycapssa.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Mycapssa
Chiesi USA, Inc. is focused on providing MYCAPSSA, an oral prescription medication designed for the long-term maintenance treatment of acromegaly. The company targets patients who have previously shown tolerance and effectiveness to treatments like octreotide or lanreotide. MYCAPSSA allows for flexible dosing and patient support resources to manage symptoms effectively. The company aims to support US residents through informative resources and patient assistance programs.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mycapssa your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Mycapssa, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Mycapssa had a recent Job posting/layoffs
Product Launch: Get notified when Mycapssa launches new products
Check out if Mycapssa is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Mycapssa
Earning: See what the market has to say on Mycapssa recently announced quarterly report
Funding: Get notified immidiatlly once Mycapssa has new funding data
Check if Mycapssa has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Reach out to Masked Content who joined Mycapssa as Masked Content
Find 3 more new buyers
Compare Similar Companies to Mycapssa
Compare insights from companies similar to Mycapssa, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Company Profile Activity
Activity Insights
Mycapssa is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Mycapssa is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Mycapssa.
Mycapssa Tech Stack
A closer look at the technologies used by Mycapssa
Mycapssa News & Media
Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide
Amryt Announces Positive Long-Term Safety and Efficacy Data confirming the role for Mycapssa® (oral octreotide) in the management of Acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotideChiasma Presents Positive Patient-Reported Outcomes Data from its MPOWERED™ Phase 3 Trial Comparing MYCAPSSA® to Long-Acting Injectables for the Maintenance Treatment of Adults with Acromegaly
--Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®-- --Data presented at AACE 2021 demonstrate patient quality of life and work productivity significantly improved in patients transitioning from injectable SSAs to MYCAPSSA®--Acentrus Specialty Contracts with Chiasma to Bring MYCAPSSA® (octreotide) to Health Systems and Hospitals in the Acentrus Network
IRVING, Texas--(BUSINESS WIRE)--Acentrus Specialty™ has finalized an agreement with Chiasma, Inc. to provide qualified Acentrus clients access to MYCAPSSA® (octreotide).
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mycapssa
Sign Up For FreeTo access detailed company insights
Chiesi USA, Inc. is focused on providing MYCAPSSA, an oral prescription medication designed for the long-term maintenance treatment of acromegaly. The company targets patients who have previously shown tolerance and effectiveness to treatments like octreotide or lanreotide. MYCAPSSA allows for flexible dosing and patient support resources to manage... Read More
